Julie Krop Sells Shares of Aquestive Therapeutics
Julie Krop sells 25,000 shares of Aquestive Therapeutics on June 23, 2026, in a planned transaction.
Key Points
- Julie Krop sold 25,000 shares of Aquestive Therapeutics, Inc. on June 23, 2026, at an average price of $5.02 per share, totaling $125,500.
- Aquestive Therapeutics, trading on NasdaqGM under AQST, has a market cap of about $592 million and a 52-week range of $2.93 to $7.55.
- Several funds, such as RTW Investments, LP and Federated Hermes, Inc., adjusted their positions in Aquestive Therapeutics recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Julie Krop sold 25,000 shares of Aquestive Therapeutics, Inc. (NasdaqGM: AQST) in a planned transaction. The sale was executed at an average price of $5.02 per share, amounting to a total value of $125,500.
Other Institutional Activity in Aquestive Therapeutics
RTW Investments, LP increased its holdings in Aquestive Therapeutics by 1,176,471 shares, ending with a total of 7,426,471 shares worth about $30.8 million, marking an 18.8% increase. Federated Hermes, Inc. also boosted its position, adding 907,517 shares to hold 2,940,339 shares valued at approximately $12.2 million, a 44.6% increase. Meanwhile, BlackRock, Inc. reduced its stake by 266,331 shares, bringing its total to 7,509,071 shares worth around $31.2 million, reflecting a 3.4% decrease. Vanguard Capital Management LLC opened a new position with 4,443,698 shares valued at $18.4 million. Balyasny Asset Management L.P. significantly increased its stake by 1,929,631 shares, now holding 2,900,570 shares worth roughly $12 million, a 198.7% rise.
Aquestive Therapeutics, Inc. Stock Down 0.6%
Shares of Aquestive Therapeutics traded near $5.03 on Wednesday. The company, with a market cap of about $592 million, operates in the healthcare sector, specializing in drug manufacturing. It has a 52-week low of $2.93 and a high of $7.55. The stock's 50-day moving average stands at $4.17, with a 200-day moving average of $4.89. Aquestive's forward P/E ratio is not meaningful as the company is not currently profitable, and it has a beta of 1.451. The company maintains a strong liquidity position with a current ratio of 4.1 and a quick ratio of 3.7.
$AQST stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Aquestive Therapeutics reported revenue of $50.3 million, with a revenue growth rate of 65.7%. Despite this growth, the company posted a negative net margin of -137.1%. The next earnings report is anticipated on August 11, 2026.
Insider Buying and Selling at Aquestive Therapeutics, Inc.
Julie Krop's sale of 25,000 shares on June 23, 2026, was part of a planned transaction at an average price of $5.02 per share. On the same day, she executed another sell transaction of 25,000 shares. Earlier, on June 15, 2026, Daniel Barber, President and CEO, sold 25,000 shares at $4.16 per share in a planned sale.
Analysts Set New Price Targets
Piper Sandler maintained a "buy" rating on Aquestive Therapeutics with an $8.00 price target on November 7, 2025. JMP Securities also maintained its "buy" rating with a higher target of $12.00 on October 9, 2025. The consensus among nine analysts is a "buy," with an average target price of $8.89.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc., based in Warren, New Jersey, is a pharmaceutical company that focuses on developing and commercializing differentiated products to solve patient therapeutic problems. The company specializes in drug delivery technologies and has a range of products, including treatments for seizures, opioid dependence, and ADHD. It employs 147 people and is led by CEO Daniel Barber.
Bottom Line
Julie Krop's recent share sale highlights ongoing insider activity at Aquestive Therapeutics. Investors keep a close eye on such transactions for insights into company sentiment. The company's stock performance and institutional activity reflect its current market positioning. Keep in mind that insider transactions are reported after they occur, and the stock's future performance may differ.
Get Aquestive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AQST, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.